GCG and metabolic dysfunction-associated steatotic liver disease: Although glucose-lowering drugs (e.g., metformin, pioglitazone, glucagon-like peptide-1 (GLP-1) analogues), antioxidants (e.g., vitamin E), lipid-lowering drugs (e.g., statins), and hepatoprotective drugs (e.g., obeticholic acid, and ursodeoxycholic acid) are currently used for the treatment of NAFLD [9,10,11,12], there are a variety of adverse effects associated with these medications such as an increase in mortality at high doses of vitamin E, risk of increased body weight and fluid retention with pioglitazone, and gastrointestinal adverse effects with GLP-1 analogues.